Mobilization and Hematopoietic Stem Cell Collection in Poor Mobilizing Patients with Lymphoma: Final Results of the German OPTIMOB Study

Katharina Kriegsmann; Max Bittrich; Sandra Sauer; Carola Tietze-Stolley; Kamran Movassaghi; Matthias Grube; Vladan Vucinic; Daniela Wehler; Andreas Burchert; Martin Schmidt-Hieber; Andreas Rank; Heinz A. Dürk; Bernd Metzner; Christoph Kimmich; Marcus Hentrich; Christian Kunz; Frank Hartmann; Cyrus Khandanpour; Maike De Wit; Udo Holtick; Michael Kiehl; Andrea Stoltefuß; Alexander Kiani; Ralph Naumann; Christian W. Scholz; Hans Joachim Tischler; Martin Görner; Franziska Brand; Martin Ehmer; Nicolaus Kröger

doi:10.1159/000531936

Mobilization and Hematopoietic Stem Cell Collection in Poor Mobilizing Patients with Lymphoma: Final Results of the German OPTIMOB Study

Katharina Kriegsmann^*, Max Bittrich, Sandra Sauer, Carola Tietze-Stolley, Kamran Movassaghi, Matthias Grube, Vladan Vucinic, Daniela Wehler, Andreas Burchert, Martin Schmidt-Hieber, Andreas Rank, Heinz A. Dürk, Bernd Metzner, Christoph Kimmich, Marcus Hentrich, Christian Kunz, Frank Hartmann, Cyrus Khandanpour, Maike De Wit, Udo HoltickMichael Kiehl, Andrea Stoltefuß, Alexander Kiani, Ralph Naumann, Christian W. Scholz, Hans Joachim Tischler, Martin Görner, Franziska Brand, Martin Ehmer, Nicolaus Kröger

^*Corresponding author for this work

7 Citations (Scopus)

Abstract

Introduction: Successful mobilization and collection of peripheral hematopoietic stem cells (HSCs) are necessary for lymphoma patients eligible for myeloablative chemotherapy with subsequent autologous stem cell transplantation (ASCT). Albeit G-CSF alone or combined with chemotherapy is well-established methods for HSC mobilization, up to 40% of the patients fail to mobilize (poor mobilizer, PM). Plerixafor (PLX) is commonly used in PM patients resulting in increased migration of HSCs into peripheral blood and thus improves the collection outcome. Methods: The prospective, multicenter, open-label, non-interventional OPTIMOB study assessed mobilization and collection parameter of patients with lymphoma or multiple myeloma to get deep insights in the treatment of those patients in clinical routine focusing on PM patients. PM was defined as follows: (1) no achievement of ≥20 CD34+ progenitor cells/μL before first apheresis, (2) PLX administration at any time point during the observational period, (3) reduction of the initially planned CD34+ progenitor cell yield as necessity due to failed mobilization or HSC collection, and (4) no performance of apheresis due to low CD34+ progenitor level. Primary objective of the study was to assess mobilization success by the proportion of PM patients achieving >2 × 106 CD34+ progenitor cells/kg body weight on the first day of apheresis. Here, the data of the lymphoma cohort are presented. Results: Out of 238 patients with lymphoma documented in the study, 32% were classified as PM. 87% of them received PLX. Demographic data revealed no obvious differences between PM and good mobilizing (GM) patients. All patients were treated highly individualized prior to mobilization. Majority of all PM patients were able to undergo apheresis (95%) and reached their individual requested CD34+ progenitor cell target (72%). 57% of the PM patients achieved >2.0 × 106 CD34+ progenitor cells/kg body weight on day 1 of apheresis and nearby 70% of them underwent ASCT. Median time to engraftment was similar in PM and GM patients of the lymphoma cohort. Conclusions: Majority of PM patients with lymphoma were successfully mobilized and underwent ASCT. Most of them received PLX during the study.

Original language	English
Journal	Transfusion Medicine and Hemotherapy
Volume	50
Issue number	5
Pages (from-to)	403-416
Number of pages	14
ISSN	1660-3796
DOIs	https://doi.org/10.1159/000531936
Publication status	Published - 21.10.2023

Funding

M.S.-H. received honoraria for consultancy activities from Celgene GmbH, Amgen GmbH, Kite/Pharma Gilead, Sanofi-Aventis Deutschland GmbH, Glaxo Smith Kline GmbH & Co. KG, Bristol Myers Squibb GmbH & Co. KG, Shionogi GmbH, Stemline Therapeutics (no individual payment) and financial support of educational meetings from Janssen-Cilag GmbH, Takeda Pharma Vertrieb GmbH & Co. KG, Novartis Pharma GmbH, Pfizer Pharma GmbH, Roche Pharma AG, Vifor Pharma Deutschland GmbH, and Celgene GmbH (no individual payment). Additionally, M.S.-H. participated in different clinical trials supported by the industry (including the OPTIMOB study). R.N. received honoraria for consultancy activities from AvenCell (formerly Cellex Patient Treatment GmbH), Simon Kucher and Partners Strategy and Marketing Consultants GmbH, and Takeda, honoraria for advisory board activities from Sanofi-Aventis Deutschland GmbH, Glaxo Smith Kline GmbH & Co. KG, Oncopeptides, Bristol Myers Squibb (Celgene), Janssen, Gilead, Amgen, honoraria for lectures from Forum Medizin Fortbildung (FOMF), Bildungsinstitut für Gesundheitsberufe Südwestfalen in Siegen (BIGS) GmbH, and honoraria for authorship from Elsevier. C.W.S. received honoraria from Bristol Myers Squibb, Celgene, Daiichi Sankyo, GILEAD, Hexal, Incyte, Janssen, Lilly, MSD, Merck Serono, Miltenyi Biotec, Novartis, Pfizer, Roche, and Takeda. H.J.T. received honoraria from Sanofi, Bristol Meyer Squibb, and Takeda. F.B. and M.E. are Employed by Sanofi-Aventis Deutschland GmbH and May Hold Stock and/or Stock Options in the Company. N.K. received honoraria and research funding from Sanofi, Bristol Myers Squibb, Neovii, Novartis, Amgen, and Riemser. A.K., K.M., A.S., M.G. (Martin Görner), F.H., H.A.D., A.R., B.M., and M.K. have no conflicts of interest to declare.

Research Areas and Centers

Research Area: Luebeck Integrated Oncology Network (LION)
Centers: University Cancer Center Schleswig-Holstein (UCCSH)

DFG Research Classification Scheme

2.22-14 Hematology, Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1159/000531936

Cite this

Kriegsmann, K., Bittrich, M., Sauer, S., Tietze-Stolley, C., Movassaghi, K., Grube, M., Vucinic, V., Wehler, D., Burchert, A., Schmidt-Hieber, M., Rank, A., Dürk, H. A., Metzner, B., Kimmich, C., Hentrich, M., Kunz, C., Hartmann, F., Khandanpour, C., De Wit, M., ... Kröger, N. (2023). Mobilization and Hematopoietic Stem Cell Collection in Poor Mobilizing Patients with Lymphoma: Final Results of the German OPTIMOB Study. Transfusion Medicine and Hemotherapy, 50(5), 403-416. https://doi.org/10.1159/000531936

@article{59d37ec30ca44a1e9f3cd3d02db248a6,

title = "Mobilization and Hematopoietic Stem Cell Collection in Poor Mobilizing Patients with Lymphoma: Final Results of the German OPTIMOB Study",

abstract = "Introduction: Successful mobilization and collection of peripheral hematopoietic stem cells (HSCs) are necessary for lymphoma patients eligible for myeloablative chemotherapy with subsequent autologous stem cell transplantation (ASCT). Albeit G-CSF alone or combined with chemotherapy is well-established methods for HSC mobilization, up to 40\% of the patients fail to mobilize (poor mobilizer, PM). Plerixafor (PLX) is commonly used in PM patients resulting in increased migration of HSCs into peripheral blood and thus improves the collection outcome. Methods: The prospective, multicenter, open-label, non-interventional OPTIMOB study assessed mobilization and collection parameter of patients with lymphoma or multiple myeloma to get deep insights in the treatment of those patients in clinical routine focusing on PM patients. PM was defined as follows: (1) no achievement of ≥20 CD34+ progenitor cells/μL before first apheresis, (2) PLX administration at any time point during the observational period, (3) reduction of the initially planned CD34+ progenitor cell yield as necessity due to failed mobilization or HSC collection, and (4) no performance of apheresis due to low CD34+ progenitor level. Primary objective of the study was to assess mobilization success by the proportion of PM patients achieving >2 × 106 CD34+ progenitor cells/kg body weight on the first day of apheresis. Here, the data of the lymphoma cohort are presented. Results: Out of 238 patients with lymphoma documented in the study, 32\% were classified as PM. 87\% of them received PLX. Demographic data revealed no obvious differences between PM and good mobilizing (GM) patients. All patients were treated highly individualized prior to mobilization. Majority of all PM patients were able to undergo apheresis (95\%) and reached their individual requested CD34+ progenitor cell target (72\%). 57\% of the PM patients achieved >2.0 × 106 CD34+ progenitor cells/kg body weight on day 1 of apheresis and nearby 70\% of them underwent ASCT. Median time to engraftment was similar in PM and GM patients of the lymphoma cohort. Conclusions: Majority of PM patients with lymphoma were successfully mobilized and underwent ASCT. Most of them received PLX during the study.",

author = "Katharina Kriegsmann and Max Bittrich and Sandra Sauer and Carola Tietze-Stolley and Kamran Movassaghi and Matthias Grube and Vladan Vucinic and Daniela Wehler and Andreas Burchert and Martin Schmidt-Hieber and Andreas Rank and D{\"u}rk, \{Heinz A.\} and Bernd Metzner and Christoph Kimmich and Marcus Hentrich and Christian Kunz and Frank Hartmann and Cyrus Khandanpour and \{De Wit\}, Maike and Udo Holtick and Michael Kiehl and Andrea Stoltefu{\ss} and Alexander Kiani and Ralph Naumann and Scholz, \{Christian W.\} and Tischler, \{Hans Joachim\} and Martin G{\"o}rner and Franziska Brand and Martin Ehmer and Nicolaus Kr{\"o}ger",

year = "2023",

month = oct,

day = "21",

doi = "10.1159/000531936",

language = "English",

volume = "50",

pages = "403--416",

journal = "Transfusion Medicine and Hemotherapy",

issn = "1660-3796",

publisher = "S. Karger AG",

number = "5",

}

Kriegsmann, K, Bittrich, M, Sauer, S, Tietze-Stolley, C, Movassaghi, K, Grube, M, Vucinic, V, Wehler, D, Burchert, A, Schmidt-Hieber, M, Rank, A, Dürk, HA, Metzner, B, Kimmich, C, Hentrich, M, Kunz, C, Hartmann, F, Khandanpour, C, De Wit, M, Holtick, U, Kiehl, M, Stoltefuß, A, Kiani, A, Naumann, R, Scholz, CW, Tischler, HJ, Görner, M, Brand, F, Ehmer, M & Kröger, N 2023, 'Mobilization and Hematopoietic Stem Cell Collection in Poor Mobilizing Patients with Lymphoma: Final Results of the German OPTIMOB Study', Transfusion Medicine and Hemotherapy, vol. 50, no. 5, pp. 403-416. https://doi.org/10.1159/000531936

TY - JOUR

T1 - Mobilization and Hematopoietic Stem Cell Collection in Poor Mobilizing Patients with Lymphoma

T2 - Final Results of the German OPTIMOB Study

AU - Kriegsmann, Katharina

AU - Bittrich, Max

AU - Sauer, Sandra

AU - Tietze-Stolley, Carola

AU - Movassaghi, Kamran

AU - Grube, Matthias

AU - Vucinic, Vladan

AU - Wehler, Daniela

AU - Burchert, Andreas

AU - Schmidt-Hieber, Martin

AU - Rank, Andreas

AU - Dürk, Heinz A.

AU - Metzner, Bernd

AU - Kimmich, Christoph

AU - Hentrich, Marcus

AU - Kunz, Christian

AU - Hartmann, Frank

AU - Khandanpour, Cyrus

AU - De Wit, Maike

AU - Holtick, Udo

AU - Kiehl, Michael

AU - Stoltefuß, Andrea

AU - Kiani, Alexander

AU - Naumann, Ralph

AU - Scholz, Christian W.

AU - Tischler, Hans Joachim

AU - Görner, Martin

AU - Brand, Franziska

AU - Ehmer, Martin

AU - Kröger, Nicolaus

PY - 2023/10/21

Y1 - 2023/10/21

N2 - Introduction: Successful mobilization and collection of peripheral hematopoietic stem cells (HSCs) are necessary for lymphoma patients eligible for myeloablative chemotherapy with subsequent autologous stem cell transplantation (ASCT). Albeit G-CSF alone or combined with chemotherapy is well-established methods for HSC mobilization, up to 40% of the patients fail to mobilize (poor mobilizer, PM). Plerixafor (PLX) is commonly used in PM patients resulting in increased migration of HSCs into peripheral blood and thus improves the collection outcome. Methods: The prospective, multicenter, open-label, non-interventional OPTIMOB study assessed mobilization and collection parameter of patients with lymphoma or multiple myeloma to get deep insights in the treatment of those patients in clinical routine focusing on PM patients. PM was defined as follows: (1) no achievement of ≥20 CD34+ progenitor cells/μL before first apheresis, (2) PLX administration at any time point during the observational period, (3) reduction of the initially planned CD34+ progenitor cell yield as necessity due to failed mobilization or HSC collection, and (4) no performance of apheresis due to low CD34+ progenitor level. Primary objective of the study was to assess mobilization success by the proportion of PM patients achieving >2 × 106 CD34+ progenitor cells/kg body weight on the first day of apheresis. Here, the data of the lymphoma cohort are presented. Results: Out of 238 patients with lymphoma documented in the study, 32% were classified as PM. 87% of them received PLX. Demographic data revealed no obvious differences between PM and good mobilizing (GM) patients. All patients were treated highly individualized prior to mobilization. Majority of all PM patients were able to undergo apheresis (95%) and reached their individual requested CD34+ progenitor cell target (72%). 57% of the PM patients achieved >2.0 × 106 CD34+ progenitor cells/kg body weight on day 1 of apheresis and nearby 70% of them underwent ASCT. Median time to engraftment was similar in PM and GM patients of the lymphoma cohort. Conclusions: Majority of PM patients with lymphoma were successfully mobilized and underwent ASCT. Most of them received PLX during the study.

AB - Introduction: Successful mobilization and collection of peripheral hematopoietic stem cells (HSCs) are necessary for lymphoma patients eligible for myeloablative chemotherapy with subsequent autologous stem cell transplantation (ASCT). Albeit G-CSF alone or combined with chemotherapy is well-established methods for HSC mobilization, up to 40% of the patients fail to mobilize (poor mobilizer, PM). Plerixafor (PLX) is commonly used in PM patients resulting in increased migration of HSCs into peripheral blood and thus improves the collection outcome. Methods: The prospective, multicenter, open-label, non-interventional OPTIMOB study assessed mobilization and collection parameter of patients with lymphoma or multiple myeloma to get deep insights in the treatment of those patients in clinical routine focusing on PM patients. PM was defined as follows: (1) no achievement of ≥20 CD34+ progenitor cells/μL before first apheresis, (2) PLX administration at any time point during the observational period, (3) reduction of the initially planned CD34+ progenitor cell yield as necessity due to failed mobilization or HSC collection, and (4) no performance of apheresis due to low CD34+ progenitor level. Primary objective of the study was to assess mobilization success by the proportion of PM patients achieving >2 × 106 CD34+ progenitor cells/kg body weight on the first day of apheresis. Here, the data of the lymphoma cohort are presented. Results: Out of 238 patients with lymphoma documented in the study, 32% were classified as PM. 87% of them received PLX. Demographic data revealed no obvious differences between PM and good mobilizing (GM) patients. All patients were treated highly individualized prior to mobilization. Majority of all PM patients were able to undergo apheresis (95%) and reached their individual requested CD34+ progenitor cell target (72%). 57% of the PM patients achieved >2.0 × 106 CD34+ progenitor cells/kg body weight on day 1 of apheresis and nearby 70% of them underwent ASCT. Median time to engraftment was similar in PM and GM patients of the lymphoma cohort. Conclusions: Majority of PM patients with lymphoma were successfully mobilized and underwent ASCT. Most of them received PLX during the study.

UR - https://www.scopus.com/pages/publications/85171804898

U2 - 10.1159/000531936

DO - 10.1159/000531936

M3 - Journal articles

AN - SCOPUS:85171804898

SN - 1660-3796

VL - 50

SP - 403

EP - 416

JO - Transfusion Medicine and Hemotherapy

JF - Transfusion Medicine and Hemotherapy

IS - 5

ER -

Mobilization and Hematopoietic Stem Cell Collection in Poor Mobilizing Patients with Lymphoma: Final Results of the German OPTIMOB Study

Abstract

Funding

Research Areas and Centers

DFG Research Classification Scheme

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this